Sarafan ChEM-H
Showing 61-80 of 139 Results
-
KC Huang
Professor of Bioengineering and of Microbiology and Immunology
On Leave from 04/01/2024 To 06/30/2024Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Possu Huang
Assistant Professor of Bioengineering
Current Research and Scholarly InterestsProtein design: molecular engineering, method development and novel therapeutics
-
Adrian Hugenmatter
Director of Protein Engineering
BioDr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. In this role he is also responsible for IMAs Protein Therapeutic module. Dr. Hugenmatter received his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich, Switzerland), where he gained initial experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Afterwards, Dr. Hugenmatter worked as a research scientist and team leader at Roche for more than a decade. During that time, he was involved in the development and optimization several antibody lead candidates for therapeutic applications in Neuroscience and Oncology.
-
Juliana Idoyaga
Assistant Professor of Microbiology and Immunology
Current Research and Scholarly InterestsThe Idoyaga Lab is focused on the function and biology of dendritic cells, which are specialized antigen-presenting cells that initiate and modulate our body’s immune responses. Considering their importance in orchestrating the quality and quantity of immune responses, dendritic cells are an indisputable target for vaccines and therapies.
Dendritic cells are not one cell type, but a network of cells comprised of many subsets or subpopulations with distinct developmental pathways and tissue localization. It is becoming apparent that each dendritic cell subset is different in its capacity to induce and modulate specific types of immune responses; however, there is still a lack of resolution and deep understanding of dendritic cell subset functional specialization. This gap in knowledge is an impediment for the rational design of immune interventions. Our research program focuses on advancing our understanding of mouse and human dendritic cell subsets, revealing their endowed capacity to induce distinct types of immune responses, and designing novel strategies to exploit them for vaccines and therapies. -
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .
-
Christine Jacobs-Wagner
Dennis Cunningham Professor, Professor of Biology and of Microbiology and Immunology
BioChristine Jacobs-Wagner is a Dennis Cunningham Professor in the Department of Biology and the ChEM-H Institute at Stanford University. She is interested in understanding the fundamental mechanisms and principles by which cells, and, in particular, bacterial cells, are able to multiple. She received her PhD in Biochemistry in 1996 from the University of Liège, Belgium where she unraveled a molecular mechanism by which some bacterial pathogens sense and respond to antibiotics attack to achieve resistance. For this work, she received multiple awards including the 1997 GE & Science Prize for Young Life Scientists. During her postdoctoral work at Stanford Medical School, she demonstrated that bacteria can localize regulatory proteins to specific intracellular regions to control signal transduction and the cell cycle, uncovering a new, unsuspected level of bacterial regulation.
She started her own lab at Yale University in 2001. Over the years, her group made major contributions in the emerging field of bacterial cell biology and provided key molecular insights into the temporal and spatial mechanisms involved in cell morphogenesis, cell polarization, chromosome segregation and cell cycle control. For her distinguished work, she received the Pew Scholars award from the Pew Charitable Trust, the Woman in Cell Biology Junior award from the American Society of Cell Biology and the Eli Lilly award from the American Society of Microbiology. She held the Maxine F. Singer and William H. Fleming professor chairs at Yale. She was elected to the Connecticut academy of Science, the American Academy of Microbiology and the National Academy of Sciences. She has been an investigator of the Howard Hughes Medical Institute since 2008.
Her lab moved to Stanford in 2019. Current research examines the general principles and spatiotemporal mechanisms by which bacterial cells replicate, using Caulobacter crescentus and Escherichia coli as models. Recently, the Jacobs-Wagner lab expanded their interests to the Lyme disease agent Borrelia burgdorferi, revealing unsuspected ways by which this pathogen grows and causes disease -
Daniel Jarosz
Associate Professor of Chemical and Systems Biology and of Developmental Biology
Current Research and Scholarly InterestsMy laboratory studies conformational switches in evolution, disease, and development. We focus on how molecular chaperones, proteins that help other biomolecules to fold, affect the phenotypic output of genetic variation. To do so we combine classical biochemistry and genetics with systems-level approaches. Ultimately we seek to understand how homeostatic mechanisms influence the acquisition of biological novelty and identify means of manipulating them for therapeutic and biosynthetic benefit.
-
Paul A. Khavari, MD, PhD
Carl J. Herzog Professor of Dermatology in the School of Medicine
Current Research and Scholarly InterestsWe work in epithelial tissue as a model system to study stem cell biology, cancer and new molecular therapeutics. Epithelia cover external and internal body surfaces and undergo constant self-renewal while responding to diverse environmental stimuli. Epithelial homeostasis precisely balances stem cell-sustained proliferation and differentiation-associated cell death, a balance which is lost in many human diseases, including cancer, 90% of which arise in epithelial tissues.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Peter S. Kim
Virginia and D. K. Ludwig Professor of Biochemistry
On Partial Leave from 09/01/2023 To 06/30/2024Current Research and Scholarly InterestsWe are studying the mechanism of viral membrane fusion and its inhibition by drugs and antibodies. We use the HIV envelope protein (gp120/gp41) as a model system. Some of our studies are aimed at creating an HIV vaccine. We are also characterizing protein surfaces that are referred to as "non-druggable". These surfaces are defined empirically based on failure to identify small, drug-like molecules that bind to them with high affinity and specificity.
-
Karla Kirkegaard
Violetta L. Horton Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsThe biochemistry of RNA-dependent RNA polymerase function, the cell biology of the membrane rearrangements induced by positive-strand RNA virus infection of human cells, and the genetics of RNA viruses, which, with their high error rates, live at the brink of error catastrophe, are investigated in the Kirkegaard laboratory.
-
Bruce Koch, Ph.D.
Director, High-Throughput Screening
Current Role at StanfordHead, ChEM-H/CSB High Throughput Screening Knowledge Center (HTSKC)
Staff Co-lead, IMA HTS Module
Adviser to the SPARK Program -
Pallavi Kompella
Res Sci, Animal Pharmacology (Basic Life Sci)
BioPh.D., Pharmaceutical Sciences, The University of Texas at Austin
Fulbright U.S. Postdoctoral Scholar, Biomedical Research Institute of Malaga, Spain -
Eric Kool
George A. and Hilda M. Daubert Professor of Chemistry
Current Research and Scholarly Interests• Design of cell-permeable reagents for profiling, modifying, and controlling RNAs
• Developing fluorescent probes of DNA repair pathways, with applications in cancer, aging, and neurodegenerative disease
• Discovery and development of small-molecule modulators of DNA repair enzymes, with focus on cancer and inflammation -
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
Lingyin Li
Associate Professor of Biochemistry
BioDr. Li is an associate professor in the Biochemistry Department and ChEM-H Institute at Stanford since 2015. Her lab works on understanding biochemical mechanisms of innate immunity and harnessing it to treat cancer. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology.
-
Michael Lin
Associate Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.
-
Kyle Loh
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel precursors in a Petri dish from embryonic stem cells. Each of these tissue precursors could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to our interests in developmental and stem cell biology, we also interested in discovering the entry receptors and target cells of deadly biosafety level 4 viruses, together with our collaborators.
Kyle attended the County College of Morris and Rutgers University, and received his Ph.D. from Stanford University (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Jonathan Z. Long
Associate Professor of Pathology
BioDr. Jonathan Long is an Associate Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). His laboratory studies signaling pathways in mammalian energy metabolism. The long-term goal of this program is to discover new molecules and pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases. Work from the laboratory has been recognized by numerous awards from the Alfred P. Sloan Foundation, the National Institutes of Health, the American Diabetes Association, and the Ono Pharma Foundation. Prior to arriving to Stanford, Dr. Long completed his Ph.D. in Chemistry at Scripps Research and his postdoctoral work at Harvard Medical School.